Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The actual benefit of ABILIFY in the treatment of schizophrenia remains substantial. |
Clinical Added Value
| moderate |
ABILIFY, like all other antipsychotics (including typical antipsychotics), provides a moderate improvement in actual benefit (IAB III) to the management of schizophrenia. |
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
0xEVd097gPsv7Za1
